Track Order   | Customer Support   | Request Book   |
International Order
The Treatment of Myeloid Malignancies with Kinase Inhibitors An Issue of Hematology Oncology Clinics of North America 1st Edition at Meripustak

The Treatment of Myeloid Malignancies with Kinase Inhibitors An Issue of Hematology Oncology Clinics of North America 1st Edition

Books from same Author: Mullally, Ann

Books from same Publisher: Elseiver

Related Category: Author List / Publisher List

  • Retail Price: ₹ 9657/- [ 5.00% off ]

    Seller Price: ₹ 9174

Sold By: Book Upload      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 5.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 5.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available


Click for International Orders
  • Provide Fastest Delivery
  • 100% Original Guaranteed
    • General Information  
    Author(s)Mullally, Ann
    PublisherElseiver
    Edition1st Edition
    ISBN9780323532358
    Pages719
    LanguageEnglish
    Publish YearSeptember 2017

    Description

    Elseiver The Treatment of Myeloid Malignancies with Kinase Inhibitors An Issue of Hematology Oncology Clinics of North America 1st Edition by Mullally, Ann

    This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!_x000D_